For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- AZ Stops Multinational PIII Trial of Zibotentan
February 21, 2011
- Astellas Withdraws Application for Darexaban in Japan
February 21, 2011
- Toho Starts New OTC Drugs Sales System Jointly with eHealthcare
February 21, 2011
- Gov't-Industry Dialogue to Resume in March
February 21, 2011
- Introduce “Compendium System”to Solve Problems of Off-label Use: Dr Fujiwara of NCC Hospital
February 21, 2011
- Halaven Approved in Singapore: Eisai
February 21, 2011
- Domestic Production of Drugs Up 3%, Highest in 10 Years
February 21, 2011
- PAFSC to Review Rivastigmine, Edoxaban, Epoetin β Pegol
February 21, 2011
- Chugai Aims to Be No. 1 in Oncology, Nephrology, Bone/Joint Diseases: Mr Nagayama
February 21, 2011
- FDA Adds Actos to List of Drugs with Potential Signals of Serious Risk
February 21, 2011
- DSP to Enhance R&D in Oncology
February 21, 2011
- Sales of Ethical Drugs Down 0.8% in December 2010
February 21, 2011
- MSD Recalls Intron
February 14, 2011
- 4 General Test Methods Harmonized
February 14, 2011
- Nitto Denko Acquires Avecia Biotechnology
February 14, 2011
- Korosho to Consider Relief System for Deaths Due to Anticancer Drugs
February 14, 2011
- Operating Profits of Top 6 Wholesalers Near Worst-Ever Levels
February 14, 2011
- Korosho to Collect ADR Reports Directly from Patients
February 14, 2011
- Drugstore Chain Operators Continue Point Services Despite JACDS Call
February 14, 2011
- Korosho's Study Group Exchanges Opinions on Safety Info. Diffusion System
February 14, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…